ArticleNature medicine2026

Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial.

Omar Nadeem et al.PubMed ↗Publisher ↗

No numbers read from the abstract.